Despite these limitations, there is a clear consensus regarding the chemokine and cytokine profile among COVID-19 patients in which IL-6, IFN, CXCL10, IL-17, TGF-β, and TNF-α are major contributors to the pulmonary immunopathology post-SARS-CoV-2 infection and stand to be important targets for therapy. The gene discussed is TGFB1; the disease is COVID-19.